All News

Hearing the words “you have cancer” while carrying a baby felt like my whole world stopped.

As we’re about to celebrate Thanksgiving 2025, I’d like to honor someone for whom I’m grateful – my son, Thomas. 

Triple-negative breast cancer often needs chemotherapy, surgery, radiation or immunotherapy, and early diagnosis can support strong outcomes.

Bernadette’s strength and optimism lifted me through my own cancer journey and reminded me how much one person’s compassion can change how I move through each day.

Dr. Li-Shiun Chen sat down with CURE to discuss study findings that overturn long-held assumptions about the impact of smoking cessation in cancer care.

Research is underway for an experimental treatment for patients with succinate dehydrogenase deficient gastrointestinal stromal tumors.

After more than 30 years since she was first diagnosed with a myeloproliferative neoplasm, Nona Baker is hopeful for the future thanks to current clinical trial landscape.

Stage 1 polycythemia vera is manageable with monitoring, phlebotomy, medication and lifestyle changes, allowing patients to live healthy, normal lives.

Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.

Surviving breast cancer changes the way you see your body. Every ache, every spot, every unfamiliar sensation becomes a quiet question: “Could it be coming back?”

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.

I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.